Advertisement

Microbicides for Prevention of HIV Infection: Clinical Efficacy Trials

  • Salim S. Abdool KarimEmail author
  • Cheryl Baxter
Chapter
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 383)

Abstract

Microbicides are an important HIV prevention technology under development, but the clinical testing of candidate products for efficacy faces many design and ethical challenges. Nevertheless, several microbicide candidates have been tested or are under development. Eight candidate products have entered late stage microbicide effectiveness trials. Following 11 disappointing effectiveness trial results of six candidate products over the past 20 years, substantial progress is now being made in microbicide development following the release of the CAPRISA 004 tenofovir gel trial results in 2010, which provided proof of concept that topical antiretroviral microbicides can prevent sexual transmission of HIV and herpes simplex type-2 infection. A trial is currently underway to confirm the effectiveness of tenofovir gel and two others have recently been initiated to assess ring formulations of the antiretroviral drug, dapivirine.

Keywords

Tenofovir Disoproxil Fumarate Effectiveness Trial Vaginal Ring Cellulose Sulfate Microbicide Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Abbas U, Glaubius R, Mubayi A, Hood G, Mellors J (2011) Predicting the Impact of ART and PrEP with overlapping regimens on HIV transmission and drug resistance in South Africa [abstract #98LB]. In: 18th conference on retroviruses and opportunistic infections, Boston, MassachusettsGoogle Scholar
  2. Abdool Karim SS, Abdool Karim Q (2011) Antiretroviral prophylaxis: a defining moment in HIV control. Lancet 378:e23–e25. doi: 10.1016/S0140-6736(11)61136-7 PubMedCentralCrossRefGoogle Scholar
  3. Abdool Karim SS, Baxter C (2010) Chapter 16: New prevention strategies under development/investigation. In: Abdool Karim SS, Abdool Karim Q (eds) HIV/AIDS in South Africa, 2nd edn. Cambridge University Press, Cape Town, pp 268–282Google Scholar
  4. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany ABM, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, on behalf of the CAPRISA 004 Trial Group (2010a) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168–1174Google Scholar
  5. Abdool Karim SS, Richardson B, Ramjee G, Hoffman I, Chirenje M, Taha T, Kapina M, Maslankowski L, Coletti A, Profy A, Moench TR, Piwowar-Manning E, Mâsse B, Hillier SL, Soto-Torres L, on behalf of the HPTN 035 Team (2010b) Safety and effectiveness of BufferGel and 0.5 % PRO2000 gel for the prevention of HIV infection in women. AIDS 25: 957–966Google Scholar
  6. Abdool Karim Q, Kharsany AB, Frohlich JA, Werner L, Mashego M, Mlotshwa M, Madlala BT, Ntombela F, Abdool Karim SS (2011a) Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. Int J Epidemiol 40:922–930. doi: 10.1093/ije/dyq176 PubMedCentralPubMedCrossRefGoogle Scholar
  7. Abdool Karim SS, Kashuba A, Werner L, Abdool Karim Q (2011b) Drug concentrations following topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 378:279–281PubMedCentralCrossRefGoogle Scholar
  8. Austin MN, Rabe LK, Hillier SL (2009) Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis 36:368–371. doi: 10.1097/OLQ.0b013e3181972397 PubMedCentralPubMedCrossRefGoogle Scholar
  9. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C (2012) Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 367:399–410PubMedCentralPubMedCrossRefGoogle Scholar
  10. CONRAD (2011a) FACTS 001: safety and effectiveness of tenofovir gel in the prevention of Human Immunodeficiency Virus (HIV-1) infection in young women and the effects of tenofovir gel on the incidence of Herpes Simplex Virus (HSV-2) infection. http://clinicaltrials.gov/ct2/show/NCT01386294. Accessed 14 Aug 2012
  11. CONRAD (2011b) Safety and effectiveness of tenofovir gel in the prevention of Human Immunodeficiency Virus (HIV-1) infection in young women and the effects of tenofovir gel on the incidence of Herpes Simplex Virus (HSV-2) infection. http://clinicaltrials.gov/ct2/show/NCT01386294. Accessed 30 Jan 2012
  12. Dezzutti CS, James VN, Ramos A, Sullivan ST, Siddig A, Bush TJ, Grohskopf LA, Paxton L, Subbarao S, Hart CE (2004) In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob Agents Chemother 48:3834–3844PubMedCentralPubMedCrossRefGoogle Scholar
  13. Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, Olayemi MO, Wang L, Nanda K, Rountree W (2008) SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS ONE 3:e1474PubMedCentralPubMedCrossRefGoogle Scholar
  14. Gengiah T, Mansoor LE, Naidoo A, Upfold M, Abdool Karim Q, Abdool Karim SS, on behalf of the CAPRISA 004 Wisebag study team (2010) The ‘Wisebag’: an innovative strategy for enhancing measurement of microbicide gel use in clinical trials. In: Microbicide 2010, Pittsburg, USAGoogle Scholar
  15. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapia M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernandez T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallas EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363:2587–2599. doi: 10.1056/NEJMoa1011205 PubMedCentralPubMedCrossRefGoogle Scholar
  16. Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ (2000) Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol 74:5577–5586PubMedCentralPubMedCrossRefGoogle Scholar
  17. Grobler AC, Abdool Karim SS (2012) Design challenges facing clinical trials of the effectiveness of new HIV prevention technologies. AIDS 26:529–532PubMedCentralPubMedCrossRefGoogle Scholar
  18. Herrera C, Shattock RJ (2013) Candidate microbicides and their mechanisms of action. Curr Top Microbiol Immunol. doi: 10.1007/82_2013_326 PubMedGoogle Scholar
  19. Hogarty K, Kasowitz A, Herold BC, Keller MJ (2007) Assessment of adherence to product dosing in a pilot microbicide study. Sex Transm Dis 34:1000–1003PubMedGoogle Scholar
  20. International Partnership for Microbicides (2012a) IPM 027: safety and efficacy trial of a dapivirine vaginal matrix ring in healthy HIV-Negative Women. http://clinicaltrials.gov/show/NCT01539226. Accessed 2 Aug 2012
  21. International Partnership for Microbicides (2012b) MTN-020: phase 3 safety and effectiveness trial of dapivirine vaginal ring for prevention of HIV-1 in women (ASPIRE). http://clinicaltrials.gov/show/NCT01617096. Accessed 2 Aug 2012
  22. Kreiss J, Ngugi E, Holmes K, Ndinya-Achola J, Waiyaki P, Roberts PL, Ruminjo I, Sajabi R, Kimata J, Fleming TR et al (1992) Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. Jama 268:477–482PubMedCrossRefGoogle Scholar
  23. Kuhn L, Susser I, Stein Z (2011) Can further placebo-controlled trials of antiretroviral drugs to prevent sexual transmission of HIV be justified? Lancet 378:285–287PubMedCrossRefGoogle Scholar
  24. Lagakos SW, Gable AR (2008) Methodological challenges in biomedical HIV prevention trials. National Academy of Sciences, Washington, DCGoogle Scholar
  25. Lewis MG, Wagner W, Yalley-Ogunro J, Greenhouse J, Profy AT (2002) Efficacy of PRO 2000 Gel in a macaque model for vaginal HIV transmission. [Abstract A-191]. In: Microbicides 2002, Antwerp, BelgiumGoogle Scholar
  26. Leynaert B, Downs AM, de Vincenzi I (1998) Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on heterosexual transmission of HIV. Am J Epidemiol 148:88–96PubMedCrossRefGoogle Scholar
  27. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, Taljaard M, Piper J, Gomez Feliciano K, Chirenje M, VOICE Study Team (2013) Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003) [Abstract #26LB]. In: 20th conference of retroviruses and opportunistic infections, Atlanta, USAGoogle Scholar
  28. Mauck CK, Van de Straten A (2008) Using objective markers to assess participant behavior in HIV prevention trials of vaginal microbicides. J Acquir Immune Defic Syndr 49:64–69PubMedCrossRefGoogle Scholar
  29. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, Jentsch U, Pool R, Chisembele M, Kapiga S et al (2010) PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 376:1329–1337PubMedCentralPubMedCrossRefGoogle Scholar
  30. McGowan I, Dezzutti C (2013) Rectal microbicide development. Curr Top Microbiol Immunol. doi: 10.1007/82_2013_325 PubMedGoogle Scholar
  31. Moench TR, O’Hanlon DE, Cone RA (2012) Evaluation of microbicide gel adherence monitoring methods. Sex Transm Dis 39:335–340PubMedCrossRefGoogle Scholar
  32. Morey TE, Wasdo S, Wishin J, Quinn B, van der Straten A, Booth M, Gonzalez D, Derendorf H, Melker RJ, Dennis DM (2012) Feasibility of a breath test for monitoring adherence to vaginal administration of antiretroviral microbicide gels. J Clin Pharmacol. doi: 10.1177/0091270011434157 Google Scholar
  33. National Institute of Allergy and Infectious Diseases (NIAID) (2011) safety and effectiveness of tenofovir 1% gel, tenofovir disproxil fumarate, and emtricitabine/tenofovir disoproxil fumarate tablets in preventing HIV in women. http://clinicaltrials.gov/ct2/show/NCT00705679. Accessed 30 Jan 2012
  34. National Institute of Allergy and Infectious Diseases (2012) MTN-008: tenofovir gel in pregnancy and lactation. http://clinicaltrials.gov/show/NCT01136759. Accessed 3 Aug 2012
  35. Nunez M, Soriano V (2005) Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect Dis 5:374–382PubMedCrossRefGoogle Scholar
  36. Pearce-Pratt R, Phillips D (1996) Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1. Biol Reprod 54:173–182PubMedCrossRefGoogle Scholar
  37. Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M, Boakye AY, Rountree W, Troxler A, Dominik R, Roddy R et al (2007) SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One 2:e1312PubMedCentralPubMedCrossRefGoogle Scholar
  38. Raymond EG, Taylor D, Cates W Jr, Tolley EE, Borasky D, Cancel A, Masse B, Bukusi EA, Johnson BR (2007) Pregnancy in effectiveness trials of HIV prevention agents. Sex Transm Dis 34:1035–1039PubMedGoogle Scholar
  39. Richardson BA, Lavreys L, Martin HL Jr, Stevens CE, Ngugi E, Mandaliya K, Bwayo J, Ndinya-Achola J, Kreiss JK (2001) Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex Transm Dis 28:394–400PubMedCrossRefGoogle Scholar
  40. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, Wong EL (1998) A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 339:504–510PubMedCrossRefGoogle Scholar
  41. Rusconi S, Moonis M, Merrill DP, Pallai PV, Neidhardt EA, Singh SK, Willis KJ, Osburne MS, Profy AT, Jenson JC, Hirsch MS (1996) Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother 40:234–236. doi: PubMedCentralPubMedGoogle Scholar
  42. Saifuddin M, Doncel G, Tsai L, Gettie A, Bhom R, Cheng-Mayer C (2008) Intravaginal administration of 6% cellulose sulfate (CS) gel prevented systemic infection in rhesus macaques in a multiple dose R5/X4 SHIV vaginal challenge model. In: Microbicides 2008, Delhi, India, 24–27 Feb 2008Google Scholar
  43. Scordi-Bello IA, Mosoian A, He C, Chen Y, Cheng Y, Jarvis GA, Keller MJ, Hogarty K, Waller DP, Profy AT, Herold BC, Klotman ME (2005) Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother 49:3607–3615PubMedCentralPubMedCrossRefGoogle Scholar
  44. Sibeko S, Baxter C, Yende N, Karim QA, Karim SS (2011) Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial. Obstet Gynecol 118:895–904. doi: 10.1097/AOG.0b013e31822be512 PubMedCentralPubMedCrossRefGoogle Scholar
  45. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, Govender S, De Kock A, Cassim N, Palanee T, Dozier G, Maguire R, Lahteenmaki P (2008) Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372:1977–1987PubMedCrossRefGoogle Scholar
  46. Smart T (2006) Report on Microbicides 2006: High rates of pregnancy pose challenges for microbicide trials. NAM aidsmap. http://www.aidsmap.com/en/news/3F76DCE3-83FA-4523-A920-5CB0829DD33A.asp. Accessed June 2006
  47. Stein ZA (1990) HIV prevention: the need for methods women can use. Am J Public Health 80:460–462Google Scholar
  48. Stone A, Harrison PF (2010) Microbicides—ways forward. Alliance for Microbicide Development, Silver SpringGoogle Scholar
  49. UNAIDS (2011) Good participatory practice guidelines for biomedical HIV prevention trials. Joint United Nations Programme on HIV/AIDS, GenevaGoogle Scholar
  50. U.S. Food and Drug Administration (2012) FDA approves first drug for reducing the risk of sexually acquired HIV infection. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm. Accessed 19 July 2012
  51. HIV Vaccines, Microbicides Resource Tracking Working Group (2012) Investing to end the AIDS epidemic: a new era for HIV prevention research and development. Progress Technology, Inc. www.hivresourcetracking.org. Accessed 13 Aug 2012
  52. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak’Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D, for the FEM-PrEP Study Group (2012) Preexposure prophylaxis for HIV infection among African women. N Engl J Med 367:411–422Google Scholar
  53. van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Abdool Karim SS et al (2002) Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360:971–977PubMedCrossRefGoogle Scholar
  54. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, Pradeep BS, Krishnan AK, Alary M, Pande B, Ramjee G, Deese J, Crucitti T, Taylor D, The CSSG (2008) Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 359:463–472. doi: 10.1056/NEJMoa0707957 PubMedCrossRefGoogle Scholar
  55. Varghese B, Maher JE, Peterman TA, Branson BM, Steketee RW (2002) Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use. Sex Transm Dis 29:38–43PubMedCrossRefGoogle Scholar
  56. Veazey RS (2008) Microbicide safety/efficacy studies in animals: macaques and small animal models. Curr Opin HIV AIDS 3:567–573. doi: 10.1097/COH.0b013e32830891bb PubMedCentralPubMedCrossRefGoogle Scholar
  57. Weber J, Nunn A, O’Connor T, Jeffries D, Kitchen V, McCormack S, Stott J, Almond N, Stone A, Darbyshire J (2001) ‘Chemical condoms’ for the prevention of HIV infection: evaluation of novel agents against SHIV(89.6PD) in vitro and in vivo. AIDS 15:1563–1568PubMedCrossRefGoogle Scholar
  58. Williams BG, Abdool Karim SS, Gouws E, Abdool Karim Q (2011) Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr 58:207–210PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Nelson R Mandela School of Medicine, CAPRISA—Centre of AIDS Programme of Research in South AfricaUniversity of KwaZulu-NatalDurbanSouth Africa
  2. 2.Department of EpidemiologyColumbia UniversityNew YorkUSA

Personalised recommendations